החברה הישראלית לנוירואימונולוגיה

The Israel society of Neuroimmunology

הצטרפות תיעוד כנסים מרכזים נוירואימונולוגיים הנחיות וניירות עמדה השתלמויות מידע לציבור תיאורי מקרה בעלי תפקידים

יו"ר: תמיר בן-חור
מזכיר: מרק הלמן
גזבר: פניוטה פטרו
חברי הוועד: אסתר גנלין-כהן, אלון מונסונגו, דן פרנקל, יואב צ'פמן, הדר קולב, אלה שיפרין-בוניאק
נשיא כבוד: עודד אברמסקי
יו"ר מייסד (1998-2009): פרופ' אריאל מילר

מן הרשת

עמוד 3 מתוך 5
<
1
2
3
4
5
>

07.01.2024

11:25

Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis

Overactivation of microglia is associated with most neurodegenerative diseases. In this study we examined whether PET-measurable innate immune cell activation predicts multiple sclerosis disease progression

Brain

07.01.2024

11:24

Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS

In this study, we assessed the relation between PIRA and neurodegenerative processes reflected by (1) longitudinal spinal cord atrophy and (2) brain paramagnetic rim lesions (PRLs)

Neurology

07.01.2024

11:23

Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis

Is disability progression independent of relapse activity (PIRA) in relapsing multiple sclerosis associated with increased rates and specific patterns of brain atrophy?

JAMA Neurol

07.01.2024

11:18

Biomarker for Disease Progression in Multiple Sclerosis

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

JAMA Neurol

07.01.2024

11:15

Relapse activity (PIRA) after a first demyelinating event in multiple sclerosis

Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis

JAMA Neurol

07.01.2024

11:13

Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis

A Systematic Review

JAMA Neurol

07.01.2024

11:11

Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis

To assess benefit and harms of cannabinoids, including synthetic, or herbal and plant‐derived cannabinoids, for reducing symptoms for adults with MS

Cochrane Database Syst Rev

19.10.2023

14:26

Multiple Sclerosis-Associated Gut Microbiome in the Israeli Diverse Populations

Associations with Ethnicity, Gender, Disability Status, Vitamin D Levels, and Mediterranean Diet

Int J Mol Sci

19.10.2023

14:20

Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases

We reviewed autoimmune diseases in MG to explore their clinical presentations and determine whether the presence of autoimmune diseases affects the disease severity and treatment strategies for MG

Frontiers in Immunology

19.10.2023

14:13

Personality Traits and Fatigue in Multiple Sclerosis

A Narrative Review

J Clin Med.

19.10.2023

14:12

Editorial: Fatigue in multiple sclerosis-A current perspective

As editors of this Research Topic, we wanted to acknowledge and give scientific space to a symptom that affects so many patients with multiple sclerosis (MS) and which has an enormous impact on the daily lives of those affected, their vocational status, and social participation

Frontiers in Neurology

19.10.2023

14:07

Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis

White matter lesions (WMLs) on brain magnetic resonance imaging (MRI) in multiple sclerosis (MS) may contribute to misdiagnosis. In chronic active lesions, peripheral iron-laden macrophages appear as paramagnetic rim lesions (PRLs)

Mult Scler

12.09.2023

11:45

Ageing and multiple sclerosis

The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas those with later onset disease face a more rapid development of permanent disability

Lancet Neurol

12.09.2023

11:44

Multiple sclerosis progression: time for a new mechanism-driven framework

Accumulating evidence suggests that the clinical course of multiple sclerosis is better considered as a continuum, with contributions from concurrent pathophysiological processes that vary across individuals and over time

Lancet Neurol

12.09.2023

11:43

A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis

Multiple sclerosis (MS) is a complex demyelinating disease of the central nervous system, presenting with different clinical forms, including clinically isolated syndrome (CIS), which is a first clinical episode suggestive of demyelination

J Pers Med

עמוד 3 מתוך 5
<
1
2
3
4
5
>

מחקרים וחדשות רפואה

טרשת נפוצה

05.11.2025, 17:42

תיאורי מקרה: מטופלי טרשת נפוצה בגיל 50 פלוס

ד״ר אלה שיפרין
טרשת נפוצה

29.10.2025, 07:05

מסלולים רפואיים טרם הופעת טרשת נפוצה

Multiple Sclerosis and Related Disorders
מן הרשת

21.10.2025, 13:19

Pediatric multiple sclerosis: Improving outcome through high-efficacy therapies

Neurotherapeutics
מן הרשת

21.10.2025, 13:18

Advancing multiple sclerosis management in older adults

nature reviews neurology

יומן ארועים

aaaדצמבר 2025	נובמבר 2025					אוקטובר 2025
א	ב	ג	ד	ה	ו	ש
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

7 הכי נקראות